pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,761 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1768Endpoints1377Fierce Biotech696BioSpace687BioPharma Dive522raps231onclive165fda recalls111
therapy area
allOncology12275Rare Disease3178Immunology2858Cardiology2711Hematology2150Pulmonology2134Vaccines
  • Patient feels exhausted despite normal labs, highlighting stress and lifestyle factors
    A family nurse practitioner recounts a visit with a 43-year-old patient who complains that she no longer has the energy she had in her twenties. The doctor notes that all of the patient’s lab resu…
    STAT · 15d agoNegative↗ source
  • Researchers warn long-term AI use may foster social isolation, call for better data access
    An opinion piece by Cornell researchers raises the possibility that extended interaction with chatbots could gradually erode social connections, urging the scientific community to investigate this…
    STAT · 15d agoNegative↗ source
← prev
page 14 of 151
next →
fda medwatch109
globenewswire health73
fda press59
1786
Psychiatry & CNS1197
Ophthalmology1036
Endocrinology & Metabolism774
Pain768
Nephrology758
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial
STAT · 15d ago↗ source
  • Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trial
    At the European Society for Medical Oncology meeting in Madrid, Roche presented data on its next‑generation KRAS G12C inhibitor in non‑small cell lung cancer. In a head‑to‑head study against compa…
    Endpoints · 15d agoPositive readoutPositive↗ source
  • Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trial
    A Phase 3 study of a personalized mRNA vaccine for melanoma, developed by Merck and Moderna, showed a substantial improvement in patient outcomes. Patients receiving the vaccine together with Merc…
    STAT · 16d agoPositive readoutPositive↗ source
  • Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to Keytruda
    Akeso announced new data from a late‑stage study of its PD‑1×VEGF bispecific antibody ivonescimab in patients with biliary tract cancer enrolled only in China. The trial showed an improvement in o…
    Endpoints · 15d agoPositive readoutPositive↗ source
  • AstraZeneca highlights broad oncology portfolio at ESMO conference
    At the European Society for Medical Oncology (ESMO) meeting in Madrid, AstraZeneca used the platform to showcase its cancer research. The company presented data on both established medicines and n…
    STAT · 15d agoPositive↗ source
  • Pfizer shifts focus after lung cancer trial setback, cites early signals in earlier-line patients; BioNTech and BMS report initial activity
    Pfizer’s late‑stage trial in non‑small cell lung cancer did not meet its primary endpoint, prompting the company to highlight a post‑hoc analysis that suggests benefit for patients treated earlier…
    Endpoints · 16d agoNeutral↗ source
  • AstraZeneca reports Tagrisso-Orpathys combo could prolong treatment for EGFR-mutant lung cancer
    At the European Society for Medical Oncology meeting, AstraZeneca said early data suggest that adding Orpathys to Tagrisso may let patients with mutant non‑small cell lung cancer continue therapy a…
    Endpoints · 15d agoPositive readoutPositive↗ source
  • #ESMO26: Merck and Moderna's cancer vaccine data were 'a triumph of science.' And now, the work begins
    MADRID — In a testament to clinicians’ interest in Merck and Moderna’s personalized cancer vaccine data at this year’s European Society for Medical Oncology conference, the presidential symposium,…
    Endpoints · 15d ago↗ source
  • Amgen's Imdelltra plus AstraZeneca's Imfinzi cuts death risk by 58% in small cell lung cancer Phase 3 trial
    Amgen reported results from a Phase 3 trial evaluating its investigational therapy Imdelltra in combination with AstraZeneca’s immunotherapy Imfinzi in patients with small cell lung cancer. The st…
    Endpoints · 16d agoPositive readoutPositive↗ source
  • Merck and Moderna present Phase 3 cancer vaccine data at ESMO26 amid Treasury proposal on China investment
    Endpoints Weekly reporter Nicole DeFeudis writes from Madrid during the ESMO26 meeting. The most anticipated presentation was a Phase 3 study of a cancer vaccine jointly developed by Merck and Mod…
    Endpoints · 17d agoNeutral↗ source
  • Tonight We Ride recalls Ultimate Forza male supplement after finding undeclared sildenafil, tadalafil and dapoxetine
    Tonight We Ride, LLC of Lakeville, Minnesota announced a voluntary recall of its Ultimate Forza male supplement capsules. The recall was triggered after testing revealed the product contains undec…
    fda recalls · 16d agoCRLNegative↗ source
  • AstraZeneca, Lilly and Bayer unveil new strategies at ESMO 2026 in Madrid
    At the European Society for Medical Oncology (ESMO) congress in Madrid, nearly 40,000 delegates gathered for the five-day meeting. AstraZeneca said it is evaluating the use of its immunotherapy Ke…
    Endpoints · 16d agoNeutral↗ source
  • Amgen and AstraZeneca present new combo data for extensive-stage small cell lung cancer at ESMO
    Day two of the European Society for Medical Oncology meeting in Madrid saw nearly 40,000 attendees gathering for the latest cancer research updates, as reported in the STAT+ newsletter. The sessio…
    STAT · 16d agoPositive readoutNeutral↗ source
  • Christina Applegate’s misdiagnosis highlights ongoing challenges in multiple sclerosis diagnosis
    Actor Christina Applegate, who was diagnosed with multiple sclerosis five years ago, recently disclosed that she was initially misdiagnosed. Her public story puts a human face on the difficulty doc…
    STAT · 17d agoNeutral↗ source
  • Opinion reflects on Theranos failures and the impracticality of its testing model
    The piece appears in STAT’s First Opinion section and is authored by Torie Bosch, who invites readers to submit letters of response to opinion essays. Bosch highlights a letter from Tyler Shultz,…
    STAT · 17d agoNeutral↗ source
  • Patient dies in Bristol Myers Squibb autoimmune CAR-T trial, raising safety concerns
    Bristol Myers Squibb reported that a participant in its Phase 1 CAR-T study for multiple sclerosis died. The trial was testing an investigational CAR-T therapy aimed at autoimmune disease. The pat…
    STAT · 17d agoNegative readoutNegative↗ source
  • US Treasury proposes rule that could bar biotech investments in China
    The Treasury Department issued a proposed rule to implement the 2025 COINS Act, which governs U.S. investment in sensitive technologies in China and other countries. The proposal places a broad ra…
    Endpoints · 18d agoRegulatoryNegative↗ source
  • Tango Therapeutics reports 82% tumor response in combo trial for advanced pancreatic cancer
    Tango Therapeutics and Revolution Medicines presented data showing that their experimental combination therapy produced tumor responses in 82% of patients with a specific form of advanced pancreati…
    STAT · 18d agoPositive readoutPositive↗ source
  • Tango’s pancreatic cancer combo shows striking promise at ESMO, building on Revolution Medicines’ earlier success
    Tango presented new data on its pancreatic cancer combination at the opening of the ESMO conference, highlighting a striking level of activity that builds on earlier success reported by Revolution…
    STAT · 17d agoPositive readoutPositive↗ source
  • Lycia Therapeutics raises $317.5 million in IPO as Merck halts sac-TMT trial
    Lycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, priced its initial public offering at about $317.5 million, bringing total proceeds to roughly $318 million. The offering marks the…
    Endpoints · 17d agoDealNeutral↗ source
  • Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trial
    A recent study of a personalized mRNA cancer vaccine showed a 42% reduction in disease recurrence for patients with melanoma compared with the standard of care. The vaccine is tailored to each pat…
    STAT · 18d agoPositive readoutPositive↗ source
  • Pathos AI secures $237M Series E funding at $3B valuation, partners with Bristol Myers on neuroscience
    Pathos AI, an AI-focused biotech based in New York, announced it has closed a Series E financing round raising $237 million. The round values the company at $3 billion, reflecting investor confide…
    Endpoints · 18d agoDealPositive↗ source
  • AI drug developer Pathos secures $237 million Series E, valuation hits $3 billion
    Pathos announced a $237 million Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The funding will support expansion beyond oncology into neurology, leveraging…
    STAT · 18d agoDealPositive↗ source